Navigation Links
BD Acquires Sirigen Group Limited
Date:8/27/2012

FRANKLIN LAKES, N.J., Aug. 27, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has acquired Sirigen Group Limited, a developer of unique polymer dyes that are used in flow cytometry and can be applied to other technologies.

Sirigen's polymer technology is based on Nobel Prize-winning research in conductive plastics and creates the potential for the development of novel dyes that are four to ten times brighter than conventional dyes – a breakthrough in the field.

"This new technology is a natural complement to our instrument platforms and reagent portfolio," said Alberto Mas, President, BD Biosciences. "We believe that the acquisition will enable us to develop a continuous cadence of novel, unique dyes and antibody specificity releases over the next two years, significantly expanding our life science research reagent portfolio with high-impact products."

"This acquisition is one more example of our pursuit of growth through innovation, in this case investing in a unique technology that enables us to differentiate our life science research reagent portfolio and add value for customers," said William A. Kozy, BD Executive Vice President.

The financial terms of the acquisition were not disclosed.  On a GAAP basis, the transaction is expected to be dilutive to FY 2012 earnings per share by approximately $0.01.  The Company is maintaining its full year EPS outlook as provided in its third quarter press release.    

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world.  BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

This press release contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding the potential impact on BD's life science research reagent portfolio and its results of operations of the acquisition of Sirigen that BD expects to occur or anticipates occurring in the future.  All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties.  Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement.  With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: the ability to successfully integrate Sirigen's operations and programs with BD's and the time and resources required to do so; difficulties inherent in product development and delays in product introductions; competitive factors, including the development of new technologies by other companies; pricing and market share pressures; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; changes in healthcare or other governmental regulation, including changes in government pricing and reimbursement policies or other cost containment reforms; as well as other factors discussed in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

Contacts:

Colleen T. White, Corporate Communications – 201-847-5369;
colleen_white@bd.com

Monique N. Dolecki, Investor Relations – 201-847-5378;
monique_dolecki@bd.com


'/>"/>
SOURCE BD (Becton, Dickinson and Company)
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elsevier Acquires Atira, a Provider of Research Management Solutions
2. Pregis acquires Inter-Pac; adds PE foam rollstock/plank capacity
3. Riordan Lewis & Haden
4. Equity Partners Acquires Nutritional Therapy Provider DCRX Infusion
5. CMC Biologics Acquires XOMAs Bay Area Manufacturing Facility
6. LycoRed Group Acquires Vitan, Strengthening its Leadership Position in the Global Natural Carotenoids Market
7. Hill-Rom Acquires Aspen Surgical Products
8. Life Technologies Acquires Pinpoint Genomics and CLIA-Approved Lung Cancer Test
9. AstraZeneca Acquires Neuroscience Assets From Link Medicine
10. Arthritis Associates of South Florida Acquires Access to Patient Health History Faster with Digital Pen Technology from Anoto and NextGen Healthcare
11. ERT Acquires invivodata to Establish the Industrys Most Experienced Provider of Clinical Outcome Assessment Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/12/2017)... 12, 2017 Kineta, Inc., a biotechnology company focused ... Vice President of R&D and Head of Virology Kristin ... Preparedness for the Northwest and Beyond meeting sponsored by ... 14, 2017 from 8:30-10:30 AM PDT at the Agora Conference ... Dr. Bedard will be joined by other leaders in ...
(Date:6/9/2017)... PALO ALTO, Calif. , June 9, 2017 /PRNewswire/ ... medical device company focused on the design, manufacture, sale ... updated the market on the progress of its commercial ... AeroForm is now available in more than one hundred ... country. AeroForm offers a needle-free alternative ...
(Date:6/8/2017)... Responding to Heath Ledger,s father,s recent call for ... Chris Cornell in May, the mental health watchdog group, ... psychiatric drug side effects search engine ... risks. The father of the late actor ... has called for tighter rules on prescription drugs. Speaking at ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. ... New York, has recently begun offering three new minimally invasive procedures to patients ... procedures and reducing downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ensuring meat ... new videos highlight the importance of correctly using a meat thermometer. The videos ... done extensive research on consumer food safety habits. Dr. Bruhn explains the variety ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ross Insurance Agency ... the Federal Emergency Management Agency’s (FEMA) recent update of flood zones, more people ... the Biggert-Waters Act was enacted to reflect the actual risk in flood zone ...
(Date:6/23/2017)... ... June 23, 2017 , ... All-Star Insurance, a family managed agency that offers ... Texas, is announcing the launch of a new charity drive to benefit women in ... United States reveal that an estimated 252, 710 new cases of invasive or high ...
(Date:6/22/2017)... ... June 22, 2017 , ... United Benefit Advisors ... Whipple & Company as its newest Partner Firm. Headquartered in Coconut Creek, Florida, ... risk while tailoring optimized benefit packages that strengthen the relationship between employer and ...
Breaking Medicine News(10 mins):